225 related articles for article (PubMed ID: 17896397)
1. The effect of drug eluting stents on cardiovascular events in patients with intermediate lesions and borderline fractional flow reserve.
Lavi S; Rihal CS; Yang EH; Fassa AA; Elesber A; Lennon RJ; Mathew V; David HR; Lerman A
Catheter Cardiovasc Interv; 2007 Oct; 70(4):525-31. PubMed ID: 17896397
[TBL] [Abstract][Full Text] [Related]
2. Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.
Onuma Y; Kukreja N; Daemen J; Garcia-Garcia HM; Gonzalo N; Cheng JM; van Twisk PH; van Domburg R; Serruys PW;
JACC Cardiovasc Interv; 2009 Jul; 2(7):603-10. PubMed ID: 19628181
[TBL] [Abstract][Full Text] [Related]
3. Baseline fractional flow reserve and stent diameter predict optimal post-stent fractional flow reserve and major adverse cardiac events after bare-metal stent deployment.
Samady H; McDaniel M; Veledar E; De Bruyne B; Pijls NH; Fearon WF; Vaccarino V
JACC Cardiovasc Interv; 2009 Apr; 2(4):357-63. PubMed ID: 19463450
[TBL] [Abstract][Full Text] [Related]
4. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
[TBL] [Abstract][Full Text] [Related]
5. Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group.
Brodie BR; Stuckey T; Downey W; Humphrey A; Bradshaw B; Metzger C; Hermiller J; Krainin F; Juk S; Cheek B; Duffy P; Smith H; Edmunds J; Varanasi J; Simonton CA;
JACC Cardiovasc Interv; 2008 Aug; 1(4):405-14. PubMed ID: 19463338
[TBL] [Abstract][Full Text] [Related]
6. Fractional flow reserve guided coronary revascularization in drug-eluting era in Thai patients with borderline multi-vessel coronary stenoses.
Angkananard T; Wongpraparut N; Tresukosol D; Panchavinin P
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S25-32. PubMed ID: 21721425
[TBL] [Abstract][Full Text] [Related]
7. One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: results from the Diabetic Argentina Registry (DEAR).
Mieres J; Fernandez-Pereira C; Risau G; Solorzano L; Pauletto R; Rodriguez-Granillo AM; Rubilar B; Stella P; Rodriguez AE
Cardiovasc Revasc Med; 2012; 13(5):265-71. PubMed ID: 22796496
[TBL] [Abstract][Full Text] [Related]
8. Drug-eluting or bare-metal stents in subjects over 75 years of age: what is the best therapeutic strategy? Data from 460 consecutive patients with 1-year outcome.
Ouldzein H; Roncalli J; Zouaoui W; Bongard V; Boudou N; Dumonteil N; Lhermusier T; Elbaz M; Puel J; Carrié D
Cardiovasc Revasc Med; 2009; 10(2):94-102. PubMed ID: 19327671
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.
Puymirat E; Mangiacapra F; Peace A; Ntarladimas Y; Conte M; Bartunek J; Vanderheyden M; Wijns W; de Bruyne B; Barbato E
Arch Cardiovasc Dis; 2013 Nov; 106(11):554-61. PubMed ID: 24231052
[TBL] [Abstract][Full Text] [Related]
10. 3-year clinical outcome of patients with chronic total occlusion treated with drug-eluting stents.
De Felice F; Fiorilli R; Parma A; Nazzaro M; Musto C; Sbraga F; Caferri G; Violini R
JACC Cardiovasc Interv; 2009 Dec; 2(12):1260-5. PubMed ID: 20129553
[TBL] [Abstract][Full Text] [Related]
11. One-year clinical outcomes in patients with chronic renal failure treated by percutaneous coronary intervention with drug-eluting stent.
Barthelemy O; Helft G; Silvain J; Bellemain-Appaix A; Beygui F; Choussat R; Berman E; Collet JP; Montalescot G; Metzger JP; Le Feuvre C
Arch Cardiovasc Dis; 2011 Dec; 104(12):604-10. PubMed ID: 22152512
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of percutaneous coronary intervention in intermediate coronary artery disease: fractional flow reserve-guided versus intravascular ultrasound-guided.
Nam CW; Yoon HJ; Cho YK; Park HS; Kim H; Hur SH; Kim YN; Chung IS; Koo BK; Tahk SJ; Fearon WF; Kim KB
JACC Cardiovasc Interv; 2010 Aug; 3(8):812-7. PubMed ID: 20723852
[TBL] [Abstract][Full Text] [Related]
13. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.
Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Cheong SS; Kim JJ; Park SW; Park SJ
JACC Cardiovasc Interv; 2008 Oct; 1(5):494-503. PubMed ID: 19463351
[TBL] [Abstract][Full Text] [Related]
14. Comparison of drug-eluting stents with bare metal stents in unselected patients with acute myocardial infarction.
Kupferwasser LI; Amorn AM; Kapoor N; Lee MS; Kar S; Cercek B; Dohad S; Mirocha J; Forrester JS; Shah PK; Makkar RR
Catheter Cardiovasc Interv; 2007 Jul; 70(1):1-8. PubMed ID: 17580366
[TBL] [Abstract][Full Text] [Related]
15. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study.
Pijls NH; Fearon WF; Tonino PA; Siebert U; Ikeno F; Bornschein B; van't Veer M; Klauss V; Manoharan G; Engstrøm T; Oldroyd KG; Ver Lee PN; MacCarthy PA; De Bruyne B;
J Am Coll Cardiol; 2010 Jul; 56(3):177-84. PubMed ID: 20537493
[TBL] [Abstract][Full Text] [Related]
16. Impact of multivessel stenting on top of percutaneous revascularization for unprotected left main disease in the drug-eluting stent era: insights from the Turin registry.
Sheiban I; Sillano D; Biondi-Zoccai G; Moretti C; Garrone P; Lombardi P; Sciuto F; Omedè P; Iacovino C; Spina CL; Trevi GP
J Cardiovasc Med (Hagerstown); 2009 Jun; 10(6):461-8. PubMed ID: 19395977
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Patient-Related and Lesion-Related Outcomes After Real-World Fractional Flow Reserve Use.
Doh JH; Nam CW; Koo BK; Park SH; Lee JH; Han JK; Yang HM; Lim HS; Yoon MH; Cho YK; Hur SH; Lee SY; Kim HS; Tahk SJ
J Invasive Cardiol; 2015 Sep; 27(9):410-5. PubMed ID: 26332875
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of drug eluting stent in patients with ST elevation myocardial infarction undergoing primary angioplasty.
Romano M; Buffoli F; Tomasi L; Corrado L; Ferrari MR; Zanini R
Catheter Cardiovasc Interv; 2008 May; 71(6):759-63. PubMed ID: 18412066
[TBL] [Abstract][Full Text] [Related]
19. Impact of renal insufficiency on safety and efficacy of drug-eluting stents compared to bare-metal stents at 6 years.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Valstar G; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P;
Catheter Cardiovasc Interv; 2012 Jul; 80(1):18-26. PubMed ID: 21735520
[TBL] [Abstract][Full Text] [Related]
20. Fractional flow reserve in unstable angina and non-ST-segment elevation myocardial infarction experience from the FAME (Fractional flow reserve versus Angiography for Multivessel Evaluation) study.
Sels JW; Tonino PA; Siebert U; Fearon WF; Van't Veer M; De Bruyne B; Pijls NH
JACC Cardiovasc Interv; 2011 Nov; 4(11):1183-9. PubMed ID: 22115657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
